Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Clearway Energy

In the grand theater of the stock market, bargain stocks have often played a leading role in captivating discerning investors. Those who understand the essence of buying robust businesses at bargain prices can attest to this strategy's exponential wealth creation opportunity.

Bargain Hunting: 3 Stocks to Buy at 52-Week Lows

Centene

HCA Healthcare

Surgery Partners

Tenet Healthcare

Universal Health Services

UnitedHealth Group

Recent growth in inpatient and outpatient services has been even higher than elevated investor expectations, Mizuho Securities analysts said in a research note Tuesday. Outpatient volume grew 8% in the second quarter, compared with the year-earlier period, while inpatient volume grew 4%, according to a Mizuho survey of more than 200 doctors in 14 specialties.

Healthcare demand outpacing investor expectations, boosting outlook for providers, Mizuho analysts say

Humana's (HUM) strength in Individual Medicare Advantage business and state-based contract wins are likely to be major tailwinds.

Why You Should Add Humana (HUM) Stock to Your Portfolio Now

Honeywell

Keurig Dr Pepper Inc

Coca-Cola

NextEra Energy

We have narrowed our search to five U.S. corporate bigwigs with negative returns in stock prices in the first half of 2023. These are: HON, HUM, KO, KDP, NEE.

Buy 5 Underperformers of 1H That Are Set to Be on a Roll in 2H

Dollar General

EPAM Systems

Some of the discount retailer Dollar General's operational flaws were exposed coming out of the pandemic. Health insurer Humana says its costs came in higher than expected, but it's been in this situation before and can resolve it.

Is It Time to Buy the S&P 500's 3 Worst-Performing Stocks in June?

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) will release its financial results for the second quarter 2023 (2Q23) on Wednesday, August 2, 2023, at 6:30 a.m. Eastern time. The company will host a conference call at 9:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2023. To participate via telephone, please register in advance using this link, https://register.vevent.com/register/BIb4689a1bdb164a4f81d868deb2ddd402 . Upon r.

Humana Inc. to Release Second Quarter 2023 Results on August 2, 2023

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Is Humana (HUM) a Buy as Wall Street Analysts Look Optimistic?

Humana (HUM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -13.84% in 4 Weeks, Here's Why You Should You Buy the Dip in Humana (HUM)

BOSTON--(BUSINESS WIRE)--Author Health launched today as one of the first platforms to provide comprehensive care and treatment for Medicare Advantage recipients with serious mental illness and substance use disorders. Approximately one in four Medicare recipients have a mental illness,1 and 40% of people in the U.S. over age 50 with serious mental illness report a lack of access to care.2 In order to meet this need, leading health and wellness company, Humana Inc. (NYSE: HUM), is the first to.

Author Health Debuts to Care for Seniors with Serious Mental Illness

Humana's share price has declined over 15% in the past two months amid the fear of rising medical costs. The increase in medical costs should be temporary, and will likely normalize after push-back procedures are being handled. The company's ongoing expansion into the healthcare services industry should expand its growth opportunities moving forward.

Humana: Rising Medical Costs Should Be Temporary

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Humana (HUM) Stock?

Costco

McDonald's

Consumer spending tightens up during an economic slowdown as consumers prioritize essentials. This list of essentials typically includes groceries, mortgage payments, and utilities.

3 Growth Stocks That Can Thrive Despite a Slowing Economy

Humana's (HUM) CenterWell business is likely to benefit from its promising plans to expand across middle Tennessee this year.

Humana's (HUM) CenterWell Unit Plans to Expand in Tennessee

Molina Healthcare

Demand for procedures like hip and knee surgeries is rising, which will leave fewer premiums in hand after paying for the procedures for the health insurers.

U.S. Health Insurers Are Tumbling: Should You be Worried?

Despite the rising demand for elective procedures, Humana (HUM) sticks to its earnings guidance.

Humana (HUM) Sees Insurance Costs at Upper Limit of Guidance

Humana says its full-year insurance segment benefit expense ratio would be at the 'top end' of a range of 86.3% to 87.3%.

Humana Says Insurance Costs to Be at 'Top End' of Estimates

Boston Scientific

Elevance Health Inc

Intuitive Surgical

Smith & Nephew

Zimmer Biomet Hlds

After a pandemic pause, hip and knee replacements are back. Long-postponed surgeries are being rescheduled, which is bad for business at insurance companies like UnitedHealth Group Inc. NYSE: UNH, but potentially good business for surgery centers like Surgery Partners Inc. NASDAQ: SGRY and companies like Zimmer Biomet Holdings Inc. NYSE: ZBH that manufacture joint-replacement technologies.

Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand

Humana Inc on Friday pegged its medical loss ratio at the top end of its full-year projected range of 86.3% to 87.3%, driven by higher-than-anticipated demand for healthcare services.

Humana sees higher health services demand driving up medical costs in 2023

Shares of Humana Inc. HUM, +1.95% fell 0.6% in premarket trading Friday, after the health insurer provided a somewhat downbeat outlook for benefit expense ratios. The company affirmed its 2023 guidance for adjusted earnings per share of “at least” $28.25, while the current FactSet EPS consensus is $28.32.

Humana stock falls after warning that insurance costs are at high end of expectations

Investors are facing one of the rarest cases in financial markets, where a deeply entrenched enterprise operating in one of the most 'defensive' sectors has left a pain trail following a 15.3% decline over the past couple of days. Humana NYSE: HUM investors were spooked after learning that the company's medical cost ratio has risen, as senior citizens are playing catch up on surgeries and other costly - insurance covered - procedures.

Humana's Fall Creates A Rare dip Buying Opportunity

CVS Health

Shares of UnitedHealth, Humana, Elevance Health and CVS Health all declined, while medical device manufacturers and hospital operators edged higher.

Health insurance stocks slide after UnitedHealth warns more surgeries will drive up medical costs

Cigna

Goldman Sachs

Insurance stocks are plunging nearly across the board today. This appears to be true whether we're talking about sector leaders like Humana (NYSE: HUM ), UnitedHealth (NYSE: UNH ), Elevance Health (NYSE: ELV ) and Cigna (NYSE: CI ) or other smaller names in the space.

Why Are Insurance Stocks HUM, UNH, ELV, CI Down Today?

Among the healthcare stocks plunging in today's session is Humana (NYSE: HUM ). Shares of HUM stock are down a whopping 12% in early afternoon trading, which is a massive move for this healthcare giant.

Why Is Humana (HUM) Stock Down 12% Today?

UnitedHealth's stock fell 7% Wednesday after saying an uptick in surgeries could squeeze revenues.

Health Insurance Stocks Tumble Over Spike In Surgeries Delayed By Pandemic

Health insurance stocks fell after a UnitedHealth Group executive's comments at a healthcare conference. UnitedHealth Group is seeing increased volumes of elective procedures for seniors.

News for Humana Stock (HUM)